Phase I dose-escalation trial of irinotecan with continuous infusion 5-FU first line, in metastatic colorectal cancer

This single-centre phase I trial was designed to determine the maximum tolerated dose of irinotecan and the recommended dose to use in combination with a fixed dose of 5-fluorouracil (5-FU) administered as a protracted venous infusion, for the first-line treatment of metastatic colorectal cancer (CR...

Descripción completa

Detalles Bibliográficos
Autores principales: Saunders, M P, Hogg, M, Carrington, B, Sjursen, A-M, Allen, J, Beech, J, Swindell, R, Valle, J W
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409945/
https://www.ncbi.nlm.nih.gov/pubmed/15452550
http://dx.doi.org/10.1038/sj.bjc.6602173

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409945/
https://www.ncbi.nlm.nih.gov/pubmed/15452550
http://dx.doi.org/10.1038/sj.bjc.6602173

Ejemplares similares